N-Acetylcysteine for non-paracetamol drug-induced liver injury:  A systemic review by Chughlay, Mohamed Farouk
Un
ive
rsi
ty
of
Ca
pe
To
wn
1	
N-ACETYLCYSTEINE	FOR	NON-PARACETAMOL
DRUG-INDUCED	LIVER	INJURY:	
A	SYSTEMATIC	REVIEW	
Student	name:	Dr	Mohamed	Farouk	Chughlay	
Student	number:	CHGMOH001	
SUBMITTED TO THE	UNIVERSITY	OF	CAPE	TOWN
In	partial	fulfillment	of	the	requirements	for	the	degree
MASTER OF MEDICINE (MMed) IN CLINICAL PHARMACOLOGY
Faculty	of Health	Sciences
UNIVERSITY OF CAPE TOWN
Date of submission: 10 September 2015
Supervisor: Dr Karen	Cohen
University:	University	of	Cape	Town,	Department	of	Medicine,	Division	of	Clinical	
Pharmacology	
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
2	
CONTENTS	
Declaration	
Dedication	and	Acknowledgements	
Acronyms	and	Abbreviations	
PART	A:	Published	Peer-reviewed	Protocol	
PART	B:	Publication-ready	Manuscript	
Ethics	Approval	
Instructions	to	Authors	(British	Journal	of	Clinical	Pharmacology)	
Turnitin	Plagiarism	Report	
3	
DECLARATION	
I,	Mohamed	Farouk	Chughlay,	hereby	declare	that	the	work	on	which	this	dissertation/thesis	is	based	is	my	
original	work	 (except	where	acknowledgements	 indicate	otherwise)	and	that	neither	 the	whole	work	nor	
any	part	of	it	has	been,	is	being,	or	is	to	be	submitted	for	another	degree	in	this	or	any	other	university.	I	
empower	the	university	 to	reproduce	for	 the	purpose	of	 research	either	 the	whole	or	any	portion	of	 the	
contents	in	any	manner	whatsoever.		
Signed	on	09	September	2015:	
4	
	
DEDICATION	
I	dedicate	 this	work	 to	my	dearest	wife,	 Sameera.	Completing	 this	MMED	could	not	have	been	achieved	
without	your	love	and	support.	
	
	
	
ACKNOWLEDGEMENTS	
I	have	been	privileged	to	work	with	an	exceptionally	talented	and	dedicated	team.	I	have	learnt	something	
unique	from	each	of	them.	Special	thanks	must	go	to	my	friend	and	co-reviewer,	Nicky	Kramer,	for	all	her	
hard	work	and	dedication	throughout	the	review	process.	
	
	
	
	
	
	
	
	
	 	
	
5	
	
ACRONYMS	AND	ABBREVIATIONS	
AASLD:	American	Association	for	the	Study	of	Liver	Diseases	
ALF:	Acute	Liver	Failure	
ALT:	Alanine	aminotransferase	
AST:	Aspartate	aminotransferase	
DDW:	Digestive	Diseases	Week	
DILI:	Drug-induced	Liver	Injury		
EASL:	European	Association	for	the	Study	of	Liver	
ICTRP:	International	Clinical	Trials	Registry	Platform	
INR:	International	Normalised	Ratio	
NAC:	N-acetylcysteine	
NAPQI:	N-acetylp-benzo-quinone	imine		
PACTR:	Pan	African	National	Clinical	Trials	Registry	
PRISMA:	Preferred	Reporting	Items	for	Systematic	reviews	and	Meta-Analyses	
RCT:	Randomised	Controlled	Trial	
RevMan:	Review	Manager	
WHO:	World	Health	Organisation	
	
6	
	
	
	 PART	A:	PUBLISHED	PEER-REVIEWED	PROTOCOL	
7	
	
	
PROTOCOL Open Access
N-acetylcysteine for non-paracetamol
drug-induced liver injury: a systematic
review protocol
Mohamed Farouk Chughlay1*, Nicole Kramer2, Mahmoud Werfalli3, Wendy Spearman4, Mark Emmanuel Engel5
and Karen Cohen1
Abstract
Background: Drug-induced liver injury (DILI) refers to acute or chronic liver injury that may occur as a consequence of
using drugs and herbal or dietary supplements. Specific therapies for DILI are limited. There is considerable evidence
for efficacy and safety of N-acetylcysteine (NAC) in management of paracetamol-induced liver injury. More recently,
research has explored the use of NAC in non-paracetamol drug-induced liver injury. It is important to summarise the
evidence of NAC for non-paracetamol DILI to determine if NAC may be considered a therapeutic option in this condition.
Methods/design: We will conduct a systematic review of the benefit and harm of NAC in non-paracetamol drug-
induced liver injury. Primary and secondary outcomes of interest are pre-specified. Primary outcomes include all-cause
mortality, mortality due to DILI, time to normalisation of liver biochemistry (e.g. return of alanine transaminase to <100
U/l and/or international normalized ratio (INR) <1.5) and adverse events. Secondary outcomes include transplantation
rate, time to transplantation, transplant-free survival and duration of hospitalisation. We will include randomized
controlled trials (RCTs) and prospective cohort studies. RCTs will contribute to the evaluation of safety and efficacy of
NAC, whereas, the cohort studies will contribute exclusively to the evaluation of safety. We will search several
bibliographic databases (including PubMed, Scopus, CINAHL, CENTRAL), grey literature sources, conference proceedings
and ongoing trials. Following data extraction and assessment of the risk of bias, we will conduct a meta-analysis if
feasible, as well as subgroup analyses. We will assess and explore clinical and statistical heterogeneity.
Discussion: The aim of this review is to provide evidence on the effectiveness and safety of NAC in non-paracetamol
DILI. We anticipate that the results could aid health care practitioners, researchers and policymakers in the decision-
making regarding the use of NAC in patients with non-paracetamol DILI.
Systematic review registration: PROSPERO CRD42014008771
Keywords: N-acetylcysteine, Acetylcysteine, Drug-induced, Hepatitis, Liver, Liver failure, Non-paracetamol,
Non-acetaminophen
Background
Drug-induced liver injury (DILI) refers to acute or chronic
liver injury that may occur as a consequence of using
drugs and herbal or dietary supplements [1, 2]. According
to recent estimates, the yearly incidence of DILI is esti-
mated to be between 14–19 cases per 100,000 [3, 4].
While this may suggest that the condition is uncommon,
there is still a considerable potential for harm. In the USA,
it is the most common cause of acute liver failure, with
11 % of cases due to idiosyncratic DILI [5]. Moreover, the
true incidence of DILI may be underestimated due to
diagnostic difficulty as well as underreporting [2].
A number of risk factors are thought to be associated
with the development of DILI. In general, older age is a
risk factor, with DILI occurring more commonly in
adults compared with children [6]. While there seems to
be a biological basis for age as a risk factor, it may also
* Correspondence: CHGMOH001@myuct.ac.za
1Division of Clinical Pharmacology, Department of Medicine, Faculty of Health
Sciences, University of Cape Town, Anzio Road, Observatory 7925 Cape Town,
South Africa
Full list of author information is available at the end of the article
© 2015 Chughlay et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chughlay et al. Systematic Reviews  (2015) 4:84 
DOI 10.1186/s13643-015-0075-6
8	
	
	
	
	
reflect that adults are more frequently exposed to poten-
tial hepatotoxins compared with children. However, age
as a risk factor does not always hold true, such that for
certain drugs, the risk is greater in children e.g. DILI
caused by valproic acid is more common in children. Fe-
males appear to be at a greater risk compared to their
male counterparts [7]. Certain genetic variations place
individuals at risk of DILI due to specific drugs e.g. isonia-
zid DILI and N-acetyltransferase 2 gene polymorphism as
well as the HLA-*B5701 genotype and flucloxacillin [8].
While these genetic variations have been shown to in-
crease the risk for the development of DILI, they do not
predict severity of injury. Pre-existing liver disease is a fur-
ther independent risk factor, with this being observed in
patients coinfected with viral hepatitis and tuberculosis
who develop DILI in response to antiviral and antituber-
culous drugs [9, 10]. Furthermore, alcohol abuse and
malnutrition are also risk factors associated with the de-
velopment of DILI [2].
The general management of DILI consists of the dis-
continuation of the offending drug in combination with
supportive treatment [2]. Patients often require pro-
longed hospital stays which may be costly to both pa-
tient and health service. Therapeutic re-challenge with
the offending drug is generally not recommended but
may be attempted in certain instances after a thorough
consideration of the risks and potential benefits. There
are specific therapies available for DILI caused by certain
drugs. However, these are limited to carnitine for val-
proic acid and N-acetylcysteine (NAC) for paracetamol
overdose [11, 12]. This limited availability highlights the
need for further research into therapies for DILI.
NAC was first used as a treatment for paracetamol
overdose in 1979 [13]. Since then, it has been firmly
established as an effective and safe treatment for this
condition [12]. NAC has also been shown to be safe and
effective outside of paracetamol overdose. NAC has been
evaluated as a treatment option for non-paracetamol
acute liver failure in adults and paediatric patients. In a
randomised clinical trial comparing NAC with placebo
in adults with non-paracetamol acute liver failure, NAC
was associated with an improvement in transplant-free
survival in a subgroup of patients with grade 1 and
grade 2 encephalopathy [14]. In a prospective study
conducted in adults with non-paracetamol acute liver
failure at a centre without the facility for transplantation,
the use of NAC was associated with a mortality benefit
[15]. In a retrospective study in paediatric patients with
non-paracetamol acute liver failure, NAC was associated
with a shorter hospital stay and improved survival post-
transplantation [16]. Furthermore, in a case series of
patients with DILI secondary to Amanita phalloides mush-
room poisoning, 10 out of 11 patients recovered fully after
receiving NAC in combination with other therapies [17].
NAC has also been evaluated for non-liver related
clinical indications. These indications include its use as a
mucolytic agent in pulmonary diseases, in the preven-
tion of radio-contrast associated nephrotoxicity and for
the treatment of certain ophthalmic conditions [18–21].
In paracetamol overdose, a form of non-idiosyncratic
DILI, the pathogenesis underlying hepatotoxicity is fairly
well understood. Here, the metabolism of paracetamol
produces an excess of the hepatotoxic metabolite N-acetyl-
p-benzo-quinone imine (NAPQI). NAPQI is normally
inactivated by hepatic glutathione; however, glutathione is
depleted in paracetamol overdose. This results in an accu-
mulation of NAPQI with consequent hepatic cell injury
and death. NAC is thought to replenish hepatic glutathi-
one stores, which forms the basis for its efficacy in this
condition [22]. In contrast, the mechanism underlying
hepatotoxicity in idiosyncratic DILI does not involve
glutathione depletion. However, the precise pathogenesis
in idiosyncratic DILI is not clearly defined [23]. The pro-
posed pathogenic mechanisms in idiosyncratic DILI in-
clude direct cell injury, immune mediated damage and
mitochondrial injury. These mechanisms, especially those
that lead to mitochondrial damage, have significant impli-
cations. Mitochondria are involved in protecting hepato-
cytes against oxidative stress from oxygen-free radicals in
the liver. The damage and loss of mitochondria leads to
an accumulation of oxygen-free radicals and subsequent
oxidative cell damage. NAC may be of benefit in this con-
text through its antioxidant effect [24, 25]. Furthermore,
additional benefits of NAC in this context involve the im-
provement of systemic haemodynamics and tissue oxygen
delivery, as well as other favourable effects on the injured
liver [26, 27].
The aim of this systematic review is to review the evi-
dence of safety and effectiveness including improvement
in time, if any, to normalisation of liver function tests
and of NAC in non-paracetamol drug-induced liver in-
jury. NAC has already been established as a safe and ef-
fective treatment for paracetamol-induced liver injury.
Recently, the research focus has shifted to investigating
the use of NAC in non-paracetamol drug-induced liver
injury. It is important to review the evidence of NAC
safety and efficacy in this setting to determine if NAC may
be considered as a treatment option in non-paracetamol
drug-induced liver injury. The evidence from this research
may then be used to inform the decisions made by policy-
makers, health care practitioners, as well as researchers in
this area.
Methods/design
This review protocol is registered in the PROSPERO
International Prospective Register of systematic reviews,
registration number CRD42014008771.
Chughlay et al. Systematic Reviews  (2015) 4:84 Page 2 of 6
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Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials (RCTs) and
prospective cohort studies. RCTs will contribute to the
evaluation of safety and efficacy of NAC, whereas, the
cohort studies will contribute exclusively to the evalu-
ation of safety.
Language and timing
No language and time restrictions will apply.
Types of participants
Human participants of any age diagnosed with non-
paracetamol drug-induced liver injury and diagnosed ac-
cording to recognised diagnostic criteria [28–31].
Types of interventions
Intervention, N-acetylcysteine administered intravenously
or orally.
Control, placebo or standard of care (as described in
the study) or alternative therapy.
There will be no restriction on dose, timing and route
of administration of NAC.
Types of outcome measures
Results must include quantitative data for outcomes
measured.
Primary outcomes All-cause mortality, mortality due to
DILI, time to normalisation of liver biochemistry (e.g. re-
turn of alanine transaminase to <100 U/l and/or inter-
national normalized ratio (INR) <1.5), adverse events
(graded using the Common Terminology Criteria for
Adverse Events) [32].
Secondary outcomes Transplantation rate, time to
transplantation, transplant-free survival, duration of
hospitalisation.
Search methods for identification of studies
We will perform a comprehensive search of databases
and conference proceedings to identify all relevant stud-
ies available by October 2014, regardless of language or
publication status. We will search both peer-reviewed
journal articles and grey literature (unpublished, internal
or non-reviewed papers and reports).
Electronic searches
We will search the following electronic databases:
Cochrane Library, Medline via PubMed, SCOPUS, Web
of Science (SciELO), and EBSCO (CINAHL, Africa-
Wide, Academic Search Premier). We will use both text
words and medical subject heading (MeSH) terms. The
literature search strategy will be adapted to suit each
database. Briefly, we will use a combination of the follow-
ing terms: N-acetylcysteine, Acetylcysteine, Drug-induced,
Hepatitis, Liver, Liver Failure, Non-paracetamol, Non-
acetaminophen.
The detailed search strategy is provided in Additional
file 1.
Conference proceedings
We will conduct a manual search of relevant abstracts
or proceedings of the following conferences (2000 to
present): American Association for the Study of Liver
Diseases (AASLD) Drug-Induced Liver Injury Confer-
ence, AASLD-FDA-NIH-PhRMA-Hepatotoxicity Special
Interest Group Conferences, European Association for
the Study of Liver (EASL), The International Liver Con-
gress and Digestive Diseases Week (DDW). If conference
abstracts are not adequately comprehensive, we will use
the information from these abstracts to search for the
full text articles. We will attempt to contact the authors
of the conference abstracts if we are unable to track
down the full text articles. If we are unable to obtain the
full text articles and contact the authors, we will list the
studies as potentially relevant.
Manual searches
We will obtain reference lists of relevant studies identi-
fied, and the full text articles reviewed for inclusion in
the review will be checked for additional information.
Searching other sources
Grey Literature will include Google Scholar, SCOPUS for
conference proceedings. www.opengrey.eu and www.grey
lit.org. For ongoing studies, we will search the Pan African
National Clinical Trials Registry (PACTR), World Health
Organisation (WHO) International Clinical Trials Regis-
try Platform (ICTRP), and ClinicalTrials.gov and NHS
Clinical Trials. Individuals and organisations working in
the field of drug-induced liver injury will be consulted for
information regarding unpublished data and work in
progress.
Data collection and analysis
The methods for data collection and analysis will be
based on the Cochrane Handbook of Systematic Reviews
for Interventions [33].
Selection of studies
Two review authors (MFC and NK) will independently
review all relevant material identified from the above
search. After reading the titles and abstracts of the iden-
tified articles, we will acquire the full text articles of all
citations deemed to meet the inclusion criteria. These
articles will be independently inspected to verify that
they meet the pre-specified inclusion criteria. We will
Chughlay et al. Systematic Reviews  (2015) 4:84 Page 3 of 6
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resolve disagreements between the two reviewers regard-
ing study eligibility through discussion with a third au-
thor (KC). For all studies excluded by the assessors, we
will describe the reasons for exclusion.
Data extraction and management
MFC and NK will use a standardised data extraction
form to extract data from the included studies and to as-
sess the study quality. Extracted information will include
administrative details, verification assessment of the
diagnosis of DILI, details of the intervention, details of
comparators, details of outcomes and information for
assessment of the risk of bias. A pilot data extraction
will be performed using the data extraction form, and
the form will be modified if required. Any discrepancies
will be resolved via discussion of the original articles
with a third author (KC). We will request missing data
from study authors. References will be managed using
Mendeley Desktop reference manager and data will be
analysed using Review Manager 5.3 (RevMan5) software.
MFC and NK will both enter data and conduct cross-
checks to ensure that there are no data entry errors.
Assessment of risk of bias in included studies
MFC and NK will independently assess the risk of bias
in each of the included studies. The assessment will in-
clude information on the following: sequence generation,
allocation concealment, blinding, incomplete outcome
data or missing data, selective outcome reporting, other
sources of bias and overall risk of bias. Each methodo-
logical component will be assessed, and the RCTs will be
described as having a low, unclear or high risk of bias,
as per the Cochrane Handbook of Systematic Reviews of
Interventions [33]. The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomized studies in
meta-analyses tool will be used for assessing the risk of
bias of the included cohort studies [34]. More specific-
ally, we will use an adapted version of the modified
NOS (see Additional file 2) to assess the risk of bias of
the included cohort studies [35]. This modified NOS in-
cludes seven questions amongst four domains of risk
assessment: methods for selecting study participants (se-
lection bias), methods to control for confounding (per-
formance bias), statistical methods (detection bias) and
methods of exposure and outcome assessment (informa-
tion bias). Risk of bias will be measured using a scale
ranging from 0 (high risk of bias) to 3 (low risk of bias),
and question-specific descriptions including examples of
varying degrees of bias are included. Items from the ori-
ginal NOS pertaining to adequacy of follow-up, selection
of participants (representativeness of cohort) and assess-
ment of outcomes will be retained in the adapted modi-
fied NOS.
The two authors will resolve disagreements in the as-
sessment of risk of bias by discussion and consensus,
consulting KC to resolve any persistent disagreements.
Measures of treatment effect
Data will be analysed using RevMan5. The type of out-
comes may include dichotomous, continuous and time-
to-event data. For dichotomous data, a summary statistic
will be calculated (e.g. odds ratio and risk ratio) with
accompanying confidence interval (e.g. 95 % CI). For
continuous data, a summary statistic such as a mean dif-
ference or standardised mean difference will be calculated.
Two methods of summarising the time-to-event data will
be considered. The first will use the methods of survival
analysis and express the intervention effect as a hazard ra-
tio. For the second method, the time-to-event data may be
analysed as dichotomous data if the status of all study par-
ticipants at a fixed time point are known and further sum-
marised as an odds ratio or risk ratio with accompanying
confidence interval. Every effort will be made to contact
the original authors or investigators of the selected articles
to assist with missing or incomplete data.
Dealing with missing data
In the cases of absent or incomplete evidence found in
the included studies, authors will be contacted for fur-
ther information. We will report unclear issues as pre-
sented rather than make assumptions. Should they be
necessary, we will be explicit about assumptions made.
Data synthesis, assessment/investigation of heterogeneity
Heterogeneity will be assessed by inspecting forest plots
initially then through the Cochran’s chi-square test using
a 10 % level of significance cut-off (due to the low power
of the test) and the I-square statistic (I2) where values
will be evaluated as follows:
0–40 % =might not be important
30–60 % =moderate
50–90 % = substantial
75–100 % = considerable
Where heterogeneity is statistically significant, subgroup
analysis using the variables of age group, sex and setting
(e.g. geographical region), as well as sensitivity analysis,
will be conducted to explore the potential sources of het-
erogeneity. Symmetry of funnel plots will be used to assess
for publication or selective reporting bias.
We will attempt primary meta-analyses of the included
RCTs for both effectiveness and harm outcomes. If meta-
analysis of RCTs is feasible, a random effects model will be
constructed. We plan to quantify the statistical reliability
of data in the cumulative meta-analysis by undertaking se-
quential analysis. Should small study effects be found, we
Chughlay et al. Systematic Reviews  (2015) 4:84 Page 4 of 6
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will conduct a meta-regression on small study effects. If
the identified RCTs are of substantial heterogeneity ren-
dering meta-analysis not feasible, the findings will be pre-
sented in narrative form and will include relevant tables
and figures to aid in data presentation. We will consider
conducting separate secondary meta-analyses for pro-
spective cohort studies limited to the outcomes of harm.
If this is not feasible, the findings from the included cohort
studies will be presented in a narrative form. All authors
will contribute to the narrative review.
In addition to evaluating all DILI participants, we also
plan to explore differences in outcomes between the fol-
lowing subgroups: sex, age strata, geographical region,
diagnostic certainty of DILI and exclusion of other pos-
sible causes, aetiology of DILI (e.g. antituberculous, HIV
antiretrovirals, antiepileptics, herbal supplements), coma
grade, severity of DILI (using severity scales such as
Drug-Induced Liver Injury Network 5-point scale where
severity of liver injury is based upon the presence of
jaundice, hospitalisation, signs of hepatic or other organ
failure, ultimate outcome and graded as 1+ mild, 2+
moderate, 3+ moderate-severe, 4+ severe, 5+ fatal) and
pattern of liver injury (hepatocellular, mixed and chole-
static). For the analyses of outcomes within subgroups,
the same methods of analyses for measuring treatment
effects as a whole will be applied.
We will use the grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach
to assess the quality of evidence [36].
Sensitivity analyses
A sensitivity analysis of the findings from primary meta-
analysis is planned, and the aim is to determine whether
the findings are robust to decisions made during the re-
view process [32]. Amongst others, we will explore the
impact of including or excluding particular studies and
the chosen method for analysis. Lastly, we will also
evaluate the impact of excluding studies deemed as hav-
ing a high risk of bias.
Presenting and reporting of results
This systematic review will be reported according to the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) statement [37].
Discussion
This review will provide evidence on the effectiveness and
safety of NAC in non-paracetamol DILI. We anticipate
that the findings could aid health care practitioners and
policymakers in the decision-making regarding the use of
NAC in patients with non-paracetamol DILI. Further-
more, the findings may benefit researchers by providing
guidance for the focus of future research through the
identification of gaps in the existing evidence and advise
on the conduct of future high-quality research through
the identification of the shortcomings in previously con-
ducted research.
Additional files
Additional file 1: Electronic search strategy. This describes the
electronic search strategy used in searching the electronic databases.
Additional file 2: Modified Newcastle-Ottawa Scale. This describes an
adapted version of a modified Newcastle-Ottawa Scale for the risk of bias
assessment of included cohort studies.
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Additional)file)1:)Electronic)search)strategy)
)
)
Search' Query'
#5'Search'(#3'AND'#4)'
#4'Search'(acetylcysteine[mh]'OR'acetylcysteine[tiab]'OR'n?acetylcysteine[tiab]'OR'n?acetyl?L?
cysteine[tiab]'OR'n?acetylcystine[tiab]'OR'acetyl'cysteine[tiab]'OR'n?acetyl'cysteine[tiab])'
#3'Search'(#1'OR'#2)'
#2'Search'(liver'failure[mh]'OR'liver'failure[tiab]'OR'hepatic'failure[tiab]'OR'hepatic'injur*[tiab])'
#1' Search'(chemically?induced'liver'failure'OR'drug?induced'liver'injury[mh]'OR'drug'induced'liver'
injur*[tiab]'OR'drug'induced'liver'disease*[tiab]'OR'drug'induced'hepatitides[tiab]'OR'drug'
induced'hepatitis[tiab]'OR'toxic'hepatitides[tiab]'OR'toxic'hepatitis[tiab])'
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Additional file 2: Adapted version of a modified Newcastle-Ottawa Scale for single use in 
specific context 
Modified Newcastle-Ottawa Scale (NOS) 
Legend 
 
 
Domain of evaluation: Methods for selecting study participants (i.e. Selection bias) 
Is the source population (cases, controls, cohorts) appropriate and representative of the population of 
interest? 
0 
(high risk of bias) 
1 2 3 
(low risk of bias) 
 
Example of low risk of bias: A consecutive sample or random selection from a population that is 
representative of the condition under study. 
Example of moderate risk of bias: A consecutive sample or random selection from a population that is 
not highly representative of the condition under study. 
Example of high risk of bias: The source population cannot be defined or enumerated (i.e. volunteering 
or self-recruitment). 
 
Domain of evaluation: Methods to control confounding (i.e. Performance bias) 
Is the sample size adequate and is there sufficient power to detect a meaningful difference in the 
outcome of interest? 
 
0 
(high risk of bias) 
1 2 3 
(low risk of bias) 
 
Example of low risk of bias: Sample size was adequate and there was sufficient power to detect a 
difference in the outcome.  
Example of high risk of bias: Sample size was small and there was not enough power to test outcome of 
interest. 
 
Did the study identify and adjust for any variables or confounders that may influence the outcome? 
0 1 2 3 
0 = Definitely no (high risk of bias) 
1 = Mostly no 
2 = Mostly yes 
3 = Definitely yes (low risk of bias) 
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(high risk of bias) (low risk of bias) 
 
Example of low risk of bias: The study identified and adjusted for all possible confounders that may 
influence estimates of association between exposure and outcome (i.e. Was the patient being treated 
for a medical condition such as chronic pain and was being prescribed opioids while on methadone 
treatment?) 
Example of moderate risk of bias: The study identified and reported possible variables that may 
influence the outcome but did not explore the interaction. 
Example of high risk of bias: The study either did not report any variables of influence or acknowledge 
variables of influence when it was clear they were present. 
 
Domain of evaluation: Statistical methods (i.e. Detection bias) 
Did the study use appropriate statistical analysis methods relative to the outcome of interest? 
0 
(high risk of bias) 
1 2 3 
(low risk of bias) 
 
Example of low risk of bias: The study reported use of appropriate statistical analysis as required (i.e. 
adjusting for an unbalanced distribution of a specific covariate among sexes, or correcting for multiple 
testing error) 
Example of moderate risk of bias: The study either used correct statistical methods but did not report 
them well, or used the incorrect methods but reported them in detail. 
Example of high risk of bias: The study did not use appropriate statistical analysis as required (i.e. did not 
adjust for an unbalanced distribution of a specific covariate among sexes, or correct for multiple testing 
error when necessary) or did not report them adequately. 
 
Is there little missing data and did the study handle it accordingly?  
0 
(high risk of bias) 
1 2 3 
(low risk of bias) 
 
Example of low risk of bias: The study acknowledged missing data to be less than 10% and specified the 
method of handling it. 
Example of moderate risk of bias: The study either had greater than 15% but they specified the method 
they used to handle it. 
Example of high risk of bias: The study had greater than 15% missing data and did not handle it at all. 
 
Domain of evaluation: Methods for measuring outcome variables (i.e. Information bias) 
Is the methodology of the outcome measurement explicitly stated and is it appropriate?  
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0 
(high risk of bias) 
1 2 3 
(low risk of bias) 
 
Example of low risk of bias: The study provides a detailed description of the outcome measure(s) which 
are appropriate for the outcome of interest. 
Example of moderate risk of bias: The study provides a somewhat complete description of outcome 
measurements and they are justified. 
Example of high risk of bias: The study provides limited information on the methods of measuring the 
outcome and the measure is not appropriate considering the outcome. 
 
Is there an objective assessment of the outcome of interest? 
0 
(high risk of bias) 
1 2 3 
(low risk of bias) 
 
Example of low risk of bias: The study used objective methods to discern the outcome status of 
participants (i.e. laboratory measurements, medical records). 
Example of moderate risk of bias: The study relied on subjective data as the primary method to discern 
outcome status of participants (i.e. self-report). 
Example of high risk of bias: The study had limited reporting about assessment of outcomes. 
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Structured	Summary	
	
Aims:	There	are	limited	therapeutic	options	for	drug-induced	liver	injury	(DILI).	N-acetylcysteine	(NAC)	is	
known	to	be	of	benefit	in	management	of	DILI	due	to	paracetamol	overdose	and	may	also	be	useful	in	the	
management	of	non-paracetamol	DILI.	Our	objective	was	to	systematically	review	evidence	for	the	use	of	
NAC	as	a	therapeutic	option	for	non-paracetamol	DILI.	
	
Methods:	We	conducted	a	systematic	review	of	the	benefit	and	harm	of	NAC	in	non-paracetamol	DILI.	We	
searched	for	randomized	controlled	trials	(RCTs)	and	prospective	cohort	studies.		We	searched	several	
bibliographic	databases	(including	PubMed,	Scopus,	CINAHL,	CENTRAL),	grey	literature	sources,	conference	
proceedings	and	ongoing	trials.	Our	pre-specified	primary	outcomes	were	all	cause	and	DILI	related	
mortality,	time	to	normalisation	of	liver	biochemistry	and	adverse	events.	Secondary	outcomes	were	
proportion	receiving	liver	transplant,	time	to	transplantation,	transplant-free	survival	and	hospitalization	
duration.	Two	reviewers	independently	assessed	studies	for	inclusion	and	quality	and	extracted	data.		
	
Results:	We	identified	one	RCT	of	NAC	versus	placebo	in	patients	with	non-paracetamol	acute	liver	failure.	
There	was	no	difference	in	the	primary	outcomes	of	overall	survival	at	3-weeks	between	NAC	[70%,	95%	
Confidence	Interval	(CI)=	60%	to	81%,	n=81]	and	placebo	(66%,	95%	CI=	56%	to	77%,	n=92).	NAC	
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significantly	improved	the	secondary	outcomes	of	transplant-free	survival	compared	with	placebo:	40%	
NAC	(95%	CI=	28%	to	51%)	versus	27%	placebo	(95%	CI=	18%	to	37%).		A	subgroup	analysis	according	to	
aetiology	found	improved	transplant-free	survival	in	patients	with	non-paracetamol	DILI;	NAC	(58%,	n=19)	
versus	placebo	(27%,	n=26);	odds	ratio	(OR)	0.27	(95%	CI=	0.076	to	0.942).	Overall	survival	was	similar	NAC	
(79%)	versus	placebo	(65%);	OR	0.50	(95%	CI=	0.13	to	1.98).		
	
Conclusion:	Current	available	evidence	is	limited	and	does	not	allow	for	any	firm	conclusions	to	be	made	
regarding	the	role	of	NAC	in	non-paracetamol	DILI.	We	therefore	highlight	the	need	for	further	research	in	
this	area.	
	
Systematic	Review	Registration:	This	review	is	registered	in	the	PROSPERO	International	Prospective	
Register	of	systematic	reviews,	registration	number	CRD42014008771.		
	
Keywords:		N-acetylcysteine,	Acetylcysteine,	Drug-induced,	Hepatitis,	Liver,	Liver	Failure,	Non-paracetamol,	
Non-acetaminophen	
	
What	is	already	known	about	this	subject	
• N-acetylcysteine	is	of	benefit	in	the	treatment	of	paracetamol-induced	liver	injury.		
• Recent	literature	suggests	a	possible	role	for	N-acetylcysteine	in	the	treatment	non-paracetamol	
drug-induced	liver	injury.		
	
What	this	study	adds	
• We	conducted	a	systematic	review	of	the	benefit	and	harm	of	NAC	in	non-paracetamol	DILI.	
• There	is	limited	evidence	supporting	the	use	of	N-acetylcysteine	in	non-paracetamol	drug-induced	
liver	injury.	
• We	therefore	highlight	the	need	for	further	research.	
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Background	
Drug-induced	liver	injury	(DILI)	refers	to	acute	or	chronic	liver	injury	that	may	occur	as	a	consequence	of	
using	drugs	and	herbal	or	dietary	supplements	[1,	2].	According	to	recent	estimates,	In	the	United	States	of	
America	(USA),	it	is	the	most	common	cause	of	acute	liver	failure	(ALF),	with	11	%	of	cases	due	to	
idiosyncratic	DILI	[3].	In	South	Africa	it	is	the	second	highest	cause	of	death	due	to	adverse	drug	reactions	in	
medical	wards	[4].	Two	recent	studies	estimated	incidence	at	between	14–19	cases	per	100,000	persons	
receiving	prescription	medication	[5,	6];	true	incidence	of	DILI	may	be	underestimated	due	to	diagnostic	
difficulty	as	well	as	underreporting	[2].	
	
The	general	management	of	DILI	consists	of	the	discontinuation	of	the	offending	drug	in	combination	with	
supportive	treatment	[2].	Patients	often	require	prolonged	hospital	stays	which	may	be	costly	to	both	
patient	and	health	service.	Therapeutic	re-challenge	with	the	offending	drug	is	generally	not	recommended	
but	may	be	attempted	in	certain	instances	after	a	thorough	consideration	of	the	risks	and	potential	
benefits.	Specific	therapies	available	for	DILI	are	limited	to	carnitine	for	valproic	acid	and	N-acetylcysteine	
(NAC)	for	paracetamol	overdose	[7,	8].													
	
NAC	was	first	used	as	a	treatment	for	paracetamol	overdose	in	1979	[9].	Since	then,	it	has	been	firmly	
established	as	an	effective	and	safe	treatment	for	this	condition	[8].	NAC	has	also	been	shown	to	be	safe	
and	effective	outside	of	paracetamol	overdose.	NAC	has	been	evaluated	as	a	treatment	option	for	non-
paracetamol	ALF	in	adults	and	paediatric	patients.	In	a	randomised	clinical	trial	comparing	NAC	with	
placebo	in	adults	with	non-paracetamol	ALF,	NAC	was	associated	with	an	improvement	in	transplant-free	
survival,	in	subgroups	of	patients	with	grade	1	and	grade	2	encephalopathy	[10].	In	a	cohort	study	
conducted	in	adults	with	non-paracetamol	ALF	at	a	centre	without	the	facility	for	transplantation,	the	use	
of	NAC	was	associated	with	a	mortality	benefit	[11].	In	a	retrospective	study	in	paediatric	patients	with	
non-paracetamol	ALF,	NAC	was	associated	with	a	shorter	hospital	stay	and	improved	survival	post-
transplantation	[12].	Furthermore,	in	a	case	series	of	patients	with	DILI	secondary	to	Amanita	phalloides	
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mushroom	poisoning,	10	of	11	patients	recovered	fully	after	receiving	NAC	in	combination	with	other	
therapies	[13].	
	
NAC	has	also	been	evaluated	for	non-liver	related	clinical	indications.	These	indications	include	its	use	as	a	
mucolytic	agent	in	pulmonary	diseases,	in	the	prevention	of	radio-contrast	associated	nephrotoxicity	and	
for	the	treatment	of	certain	ophthalmic	conditions	[14–17].	
	
In	paracetamol	overdose,	a	form	of	non-idiosyncratic	DILI,	the	pathogenesis	underlying	hepatotoxicity	is	
fairly	well	understood.	Here,	the	metabolism	of	paracetamol	produces	an	excess	of	the	hepatotoxic	
metabolite	N-acetylp-benzo-quinone	imine	(NAPQI).	NAPQI	is	normally	inactivated	by	hepatic	glutathione;	
however,	glutathione	is	depleted	in	paracetamol	overdose.	This	results	in	an	accumulation	of	NAPQI	with	
consequent	hepatic	cell	injury	and	death.	NAC	is	thought	to	replenish	hepatic	glutathione	stores,	which	
forms	the	basis	for	its	efficacy	in	this	condition	[18].	In	contrast,	the	mechanism	underlying	hepatotoxicity	
in	idiosyncratic	DILI	does	not	involve	glutathione	depletion.	However,	the	precise	pathogenesis	in	
idiosyncratic	DILI	is	not	clearly	defined	[19].	The	proposed	pathogenic	mechanisms	in	idiosyncratic	DILI	
include	direct	cell	injury,	immune	mediated	damage	and	mitochondrial	injury.	These	mechanisms,	
especially	those	that	lead	to	mitochondrial	damage,	have	significant	implications.	Mitochondria	are	
involved	in	protecting	hepatocytes	against	oxidative	stress	from	oxygen-free	radicals	in	the	liver.	The	
damage	and	loss	of	mitochondria	leads	to	an	accumulation	of	oxygen-free	radicals	and	subsequent	
oxidative	cell	damage.	NAC	may	be	of	benefit	in	this	context	through	its	antioxidant	effect	[20,	21].	
Furthermore,	additional	benefits	of	NAC	in	this	context	involve	the	improvement	of	systemic	
haemodynamics	and	tissue	oxygen	delivery,	as	well	as	other	favourable	effects	on	the	injured	
liver	[22,	23].	
	
The	aim	of	this	systematic	review	was	to	synthesise	the	evidence	of	safety	and	efficacy	including	
improvement	in	time,	if	any,	to	normalisation	of	liver	function	tests	and	of	NAC	in	non-paracetamol	DILI.	
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NAC	has	already	been	established	as	a	safe	and	effective	treatment	for	paracetamol-induced	liver	injury.	
Recently,	the	research	focus	has	shifted	to	investigating	the	use	of	NAC	in	non-paracetamol	drug-induced	
liver	injury.	It	is	important	to	review	the	evidence	of	NAC	safety	and	efficacy	in	this	setting	to	determine	if	
NAC	may	be	considered	as	a	treatment	option	in	non-paracetamol	DILI.	The	evidence	from	this	research	
may	then	be	used	to	inform	the	decisions	made	by	policymakers,	health	care	practitioners,	as	well	as	
researchers	in	this	area.	
	
Methods/Design	
This	review	is	registered	in	the	PROSPERO	International	Prospective	Register	of	systematic	reviews,	
registration	number:	CRD42014008771.	The	protocol	was	peer	reviewed	[24].		
	
Criteria	for	considering	studies	for	this	review	
Types	of	studies	
We	included	randomized	controlled	trials	(RCTs)	and	prospective	cohort	studies.		
	
Language	and	Timing	
No	language	and	time	restrictions	applied.	
	
Types	of	participants	
Human	participants	of	any	age	diagnosed	with	non-paracetamol	DILI,	diagnosed	according	to	recognised	
diagnostic	criteria	[25–28].		
	
Types	of	interventions	
Intervention:	NAC	administered	intravenously	or	orally.	Control:	placebo	or	standard	of	care	(as	described	
in	the	study)	or	alternative	therapy.	
There	were	no	restrictions	on	dose,	timing	and	route	of	administration	of	NAC.	
23	
	
Types	of	outcome	measures	
Primary	outcomes			
All-cause	mortality,	mortality	due	to	DILI,	time	to	normalisation	of	liver	biochemistry	(e.g.	return	of	alanine	
transaminase	to	<	100	U/l	and/or	International	Normalised	Ratio	(INR)	<	1.5),	adverse	events	(graded	using	
the	Common	Terminology	Criteria	for	Adverse	Events)	[29].	
Secondary	outcomes			
Transplantation	rate,	time	to	transplantation,	transplant-free	survival,	duration	of	hospitalisation.	
	
Search	Methods	for	identification	of	studies	
We	performed	a	comprehensive	search	in	June	2015	of	electronic	databases	and	conference	proceedings	
to	identify	all	relevant	studies,	regardless	of	language	or	publication	status.	We	searched	both	peer-
reviewed	journal	articles	and	grey	literature	(unpublished,	internal	or	non-reviewed	papers	and	reports).	
	
Electronic	Searches		
We	searched	the	following	electronic	databases:	Cochrane	Library;	Medline	via	PubMed;	SCOPUS;	Web	of	
Science	(SciELO);	EBSCO	(CINAHL,	Africa-Wide,	Academic	Search	Premier).		We	used	both	text	words	and	
medical	subject	heading	(MeSH)	terms.	The	literature	search	strategy	was	adapted	to	suit	each	database.	
Briefly,	we	used	a	combination	of	the	following	terms:		N-acetylcysteine,	Acetylcysteine,	Drug-induced,	
Hepatitis,	Liver,	Liver	Failure,	Non-paracetamol,	Non-acetaminophen.		
	
Conference	proceedings	
We	conducted	a	manual	search	of	relevant	abstracts	or	proceedings	of	the	following	conferences	(2000	to	
2015):	American	Association	for	the	Study	of	Liver	Diseases	(AASLD)	Drug-Induced	Liver	Injury	Conference,	
AASLD-FDA-NIH-PhRMA-Hepatotoxicity	Special	Interest	Group	Conferences,	European	Association	for	the	
Study	of	Liver	(EASL),	The	International	Liver	Congress	and	Digestive	Diseases	Week	(DDW).		
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Searching	other	sources	
We	searched	Google	Scholar;	SCOPUS	for	conference	proceedings;	and	www.opengrey.eu	and	
www.greylit.org	for	grey	literature.	For	ongoing	studies,	we	searched	the	Pan	African	National	Clinical	Trials	
Registry	(PACTR);	World	Health	Organisation	(WHO)	International	Clinical	Trials	Registry	Platform	(ICTRP);	
ClinicalTrials.gov	and	NHS	Clinical	Trials.		Individuals	and	organisations	working	in	the	field	of	drug-induced	
liver	injury	were	consulted	for	information	regarding	unpublished	data	and	work	in	progress.	
	
Data	collection	and	analysis	
The	methods	for	data	collection	and	analysis	are	based	on	the	Cochrane	Handbook	of	Systematic	Reviews	
for	Interventions	[30].	
	
Selection	of	studies		
Two	review	authors	(MFC	and	NK)	independently	reviewed	all	relevant	material	identified	from	the	above	
search.	After	reading	the	titles	and	abstracts	of	the	identified	articles,	we	acquired	the	full	text	articles	of	all	
citations	deemed	to	meet	the	inclusion	criteria.	These	articles	were	independently	inspected	to	verify	that	
they	met	the	pre-specified	inclusion	criteria.	We	resolved	disagreements	between	the	two	reviewers	
regarding	study	eligibility	through	discussion	with	a	third	author	(KC).		
	
Data	extraction	and	management	
Two	authors	(MFC	and	NK)	used	a	standardised	data	extraction	form	to	extract	data	from	the	included	
study	and	to	assess	study	quality.	Any	discrepancies	were	resolved	via	discussion	of	the	original	article	with	
a	third	author.	We	requested	additional	data	from	study	authors.	References	were	managed	using	
Mendeley	Desktop	reference	manager.	We	prepared	our	review	using	Review	Manager	5.3	(RevMan5)	
software	[31].	
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Assessment	of	risk	of	bias	in	included	studies	
MFC	and	NK	independently	assessed	the	risk	of	bias	in	the	included	study.	The	assessment	included	
information	on:	sequence	generation,	allocation	concealment,	blinding,	incomplete	outcome	data	or	
missing	data,	selective	outcome	reporting,	other	sources	of	bias,	and	overall	risk	of	bias.	Each	
methodological	component	was	assessed	and	the	study	was	described	as	having	a	low,	unclear,	or	high	risk	
of	bias,	as	per	the	Cochrane	Handbook	of	Systematic	Reviews	of	Interventions	[30].	The	two	authors	
resolved	disagreements	in	the	assessment	of	risk	of	bias	by	discussion	and	consensus,	consulting	a	third	
reviewer,	KC	to	resolve	any	persistent	disagreements.	
	
Measures	of	treatment	effect	
We	planned	to	conduct	our	data	analysis	using	Review	Manager	Version	5.3	[31].	We	present	the	data	from	
the	included	study	with	respect	to	overall	survival	and	transplant-free	survival	in	the	overall	study	
population	with	acute	liver	failure.	We	proceeded	to	calculate	the	odds	ratios	and	95%	CI	for	the	outcomes	
of	overall	survival	and	transplant-free	survival	for	the	DILI	subgroup.		
	
Data	synthesis,	assessment	of	heterogeneity	and	sensitivity	analyses	
In	view	of	limited	available	data,	we	could	not	conduct	meta-analysis;	assess	heterogeneity	or	sensitivity	
analyses.		
	
Presenting	and	reporting	of	results	
This	systematic	review	is	reported	according	to	the	Preferred	Reporting	Items	for	Systematic	reviews	and	
Meta-Analyses	(PRISMA)	statement	[32].		We	used	the	Grading	of	Recommendations	Assessment,	
Development	and	Evaluation	(GRADE)	approach	to	assess	the	quality	of	the	evidence	and	summarise	
relevant	study	outcomes	[33].	
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Results	
Results	of	Search	
Figure	1	shows	the	flow	diagram	for	study	inclusion.	A	total	of	691	records	were	identified	through	the	
search	until	June	2015.	After	screening	titles	and	abstracts,	we	excluded	687	records	leaving	4	articles	for	
full-text	review.	We	excluded	3	further	articles	after	full-text	review,	and	identified	1	article	from	which	we	
could	extract	data	for	inclusion	in	a	qualitative	analysis.	We	also	identified	one	ongoing	placebo-controlled	
trial	of	NAC	for	DILI	due	to	first-line	tuberculosis	treatment,	still	recruiting	[34].	
	
Characteristics	of	included	study	(See	Table	1)	
The	included	study	was	a	randomised,	double-blind,	placebo-controlled	trial	investigating	a	72-hour	
intravenous	infusion	of	NAC	as	treatment	for	adults	with	non-paracetamol	ALF,	at	multiple	sites	in	the	USA	
[10].	ALF	was	defined	in	the	study	as	encephalopathy	with	accompanying	coagulopathy.	Randomisation	
was	stratified	by	hepatic	encephalopathy	grade	(1-2	versus	3–4)	and	study	site.	The	study	enrolled	173	
participants	and	randomly	assigned	81	participants	to	receive	NAC	and	92	participants	to	receive	placebo.	
After	randomisation,	an	infusion	of	either	5%	dextrose	with	NAC	or	5%	dextrose	only	(placebo)	was	
administered.	The	primary	outcome	was	overall	survival	at	3	weeks.	Although	not	listed	as	an	outcome	of	
interest,	the	study	did	report	on	rates	of	adverse	events	in	study	participants.		
	
Effect	of	NAC	on	outcomes	in	overall	study	population	(participants	with	non-paracetamol	ALF):	Overall	
survival	at	3	weeks	was	similar	for	the	NAC	and	placebo	groups;	57/81	(70%;	95%	CI	60%	to	81%);	versus	
61/92	(66%;	95%	CI	56%	to	77%),	Chi	squared	p	=	0.283.	In	contrast,	transplant-free	survival	was	greater	in	
the	NAC	group	than	the	placebo	group;	32/81	(40%;	95%	CI	28%	to	51%);	versus	25/92	(27%;	95%	CI	18%	to	
37%),	Chi	squared	p=0.043.	In	a	secondary	analysis,	transplant-free	survival	was	stratified	by	coma	grade.		
In	patients	with	coma	grade	I–II	survival	was	higher	in	the	NAC	group	than	the	placebo	group;	30/58	(52%;	
95%	CI=	38%	to	65%);	versus	17/56	(30%;	95%	CI	17%	to	43%),	p=0.010,	with	an	odds	ratio	(OR)	of	2.46	
(95%	CI=	1.14	to	5.30).	In	contrast	in	participants	with	coma	grades	III–IV	transplant-free	survival	was	lower	
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in	the	NAC	group	but	this	did	not	reach	statistical	significance;	2/23	(9%;	95%	CI	0%	to	22%);	versus	8/36	
(22%;	95%	CI	7%	to	37%),	p=	0.912,	OR	0.33	(95%	CI=	0.06	to	1.74).	The	difference	in	odds	ratios	according	
to	coma	grade	was	statistically	significant	(p=	0.012).	Transplantation	rates	were	26/81	(32%;	95%	CI=	21%	
to	43%)	in	the	NAC	group	and	41/92	(45%;	95%	CI	34%	to	55%)	in	the	placebo	group,	p=0.09).			Rates	of	
adverse	events	were	similar	between	groups;	nausea	and	vomiting	was	more	common	in	the	NAC	than	the	
placebo	group,	11/81	(14%;	95%	CI	6%	to	22),	versus	4/92	(4%;	95%	CI	0%,	9%),	p=	0.031.In	total,	there	
were	5	early	discontinuations	of	therapy	due	to	side-effects	possibly	due	to	the	drug,	4	due	to	NAC.	
	
	Effect	of	NAC	on	outcomes	in	subgroup	with	ALF	due	to	non-paracetamol	DILI:	A	subgroup	analysis	by	
aetiology	of	ALF	was	conducted.	Non-paracetamol	DILI	was	the	largest	aetiological	subgroup	with	45	
participants,	of	which	19	received	NAC	and	26	received	placebo.	Outcome	data	on	the	45	DILI	participants	
were	limited	to	overall	survival	and	transplant-free	survival.	There	were	4	deaths	in	the	NAC	arm	compared	
with	9	deaths	in	the	placebo	arm,	which	corresponded	with	an	overall	survival	of	79%	(n=15)	in	the	NAC	
arm	and	65%	(n=17)	in	the	placebo	arm,	with	an	odds	ratio	of	0.50	(95	%	CI=	0.13,	1.98,	p=0.33),	and	risk	
ratio	for	death	of	0.61	(95	%	CI=	0.22	to	1.68.	p=0.34).	Transplant-free	survival	was	higher	in	the	
participants	with	non-paracetamol	DILI	treated	with	NAC	than	those	treated	with	placebo;	58%	(n=11)	
versus	27%	(n=7),	with	an	odds	ratio	of	(95	%	CI:	0.076	to	0.942,	p=0.04),	and	risk	ratio	for	death	of	0.57	
(95%	CI	0.32	to	1.03,	p=0.06).	The	study	was	not	powered	to	detect	differences	within	the	DILI	subgroups.	
	
Risk	of	Bias	in	included	study		
We	graded	the	overall	risk	of	bias	in	the	study	as	“unclear”.	See	Table	2	for	further	details	regarding	risk	of	
bias	assessment.		
	
Quality	of	the	Evidence	
The	GRADE	assessment	of	the	quality	of	the	evidence	indicated	that	the	evidence	for	the	various	outcomes	
to	be	of	“very	low”	or	“low”	quality.	See	Table	3	for	the	details	of	the	GRADE	assessment.	
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Characteristics	of	excluded	studies	(See	Table	3)	
The	first	excluded	study	was	a	small	open-label	RCT	conducted	in	Iran	that	investigated	the	
hepatoprotective	effect	of	NAC	in	antituberculous	DILI	[35].	This	study	was	excluded	on	the	basis	that	it	
investigated	the	use	of	NAC	in	the	prevention	of	DILI,	as	opposed	to	the	treatment	of	DILI.		
	
The	second	excluded	study	was	a	multicentre,	randomised,	double	masked,	placebo-controlled	trial	
investigating	NAC	as	treatment	for	non-paracetamol	ALF	in	paediatric	participants	[36].	Of	relevance	to	our	
review	is	that	this	study	included	a	subgroup	analysis	according	to	the	aetiology	of	ALF.	Non-paracetamol	
DILI	was	included	in	the	aetiology	of	ALF	and	although	there	were	3	cases	of	ALF	secondary	to	non-
paracetamol	DILI	in	the	placebo	group,	there	were	no	cases	of	ALF	secondary	to	non-paracetamol	DILI	
amongst	those	who	received	NAC.	Therefore,	we	excluded	this	study	on	the	basis	that	it	could	not	provide	
evaluable	data	for	our	review.	
	
The	third	excluded	study	was	a	cohort	study	investigating	NAC	as	treatment	in	non-paracetamol	ALF	[11].	
This	study	was	excluded	on	the	basis	that	it	included	a	comparison	with	retrospective	controls,	and	
therefore	did	not	meet	our	inclusion	criteria	of	being	a	prospective	cohort	study.	
	
Discussion	
After	systematic	review	of	published	and	unpublished	literature,	we	identified	only	one	study	addressing	
efficacy	and	safety	of	NAC	in	non-paracetamol	DILI.		Participants	with	non-paracetamol	DILI	were	a	
subgroup	in	this	randomized	controlled	trial.		This	subgroup	analysis	only	addressed	one	of	our	primary	
endpoints	(overall	survival)	and	found	no	difference	in	this	subgroup,	but	was	underpowered	for	this	
comparison.	Additionally,	GRADE	assessment	indicated	the	evidence	for	this	endpoint	to	be	of	“very	low”	
quality.	Based	on	this	study’s	findings	NAC	may	be	of	benefit	in	treatment	of	non-paracetamol	DILI	in	
improving	the	secondary	endpoint	of	transplant	free	survival.	Thus,	we	cannot	draw	firm	conclusions	on	
the	efficacy	of	NAC	in	management	of	non-paracetamol	DILI,	on	the	basis	of	limited	low	quality	outcome	
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data	confined	to	this	small	subgroup.	Findings	may	not	be	generalizable	to	patients	with	less	severe	forms	
of	liver	injury.	Patients	with	DILI	present	on	a	spectrum	from	mild	liver	injury	to	severe	liver	injury	(ALF).	We	
found	no	studies	exploring	the	benefit	of	NAC	in	patients	with	less	severe	forms	of	liver	injury.	A	final	
limitation	concerns	the	methodological	quality,	with	the	study	deemed	as	having	an	overall	“unclear”	risk	
of	bias.			
	
The	strengths	of	our	review	include	the	use	of	a	comprehensive	search,	thereby	limiting	the	likelihood	that	
we	missed	any	potentially	relevant	studies.	In	addition,	eligibility	for	study	inclusion,	data	extraction	and	
the	risk	of	bias	assessment	was	carried	out	by	two	authors	independently,	thereby	reducing	the	chances	of	
bias	in	our	review	process.	
	
This	review	has	highlighted	the	need	for	further	research	to	investigate	the	role	of	NAC	in	non-paracetamol	
DILI.	There	is	a	clear	need	for	prospective	studies	with	sufficient	sample	sizes	that	enrol	participants	with	
varying	grades	of	severity	of	DILI.	However,	there	may	be	certain	challenges	in	undertaking	these	studies	
such	as	the	difficulty	in	enrolling	sufficient	numbers	of	participants	as	a	consequence	of	diagnostic	difficulty	
and	underreporting	of	DILI	[2].		
We	found	an	ongoing	placebo-controlled	RCT	currently	enrolling	in	South	Africa	attempting	to	address	this	
research	gap,	by	investigating	the	role	of	NAC	in	participants	with	antituberculous	DILI	[34].	Low-resource	
settings	such	as	South	Africa	have	a	high	prevalence	of	tuberculosis	with	accompanying	high	rates	of	
antituberculous	DILI	between	5-33%	of	patients	[37].	Death	may	be	a	consequence	of	DILI	and	this	was	
highlighted	in	a	recently	published	cross-sectional	survey	in	hospitalised	patients,	which	found	DILI	to	be	
the	second	most	common	adverse	drug	reaction	contributing	to	death,	with	antituberculous	drugs	being	
implicated	in	the	majority	of	DILI	cases	[4].	
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Conclusion	
Our	review	has	highlighted	a	paucity	of	data,	limited	to	a	single	RCT	in	non-paracetamol	ALF	suggesting	a	
trend	for	improved	transplant	and	overall	survival	in	a	subgroup	of	participants	with	non-paracetamol	DILI.	
However,	the	evidence	was	graded	as	“low”	or	“very	low”	quality,	and	the	study	was	not	powered	to	detect	
differences	in	this	subgroup	with	DILI.	Therefore,	due	to	the	limited	available	evidence,	we	are	unable	to	
conclusively	determine	if	there	is	a	role	for	NAC	in	patients	with	non-paracetamol	DILI.	Thus,	we	are	unable	
to	make	recommendations	for	clinical	practice	and	emphasise	the	need	for	high	quality	prospective	RCTs	in	
this	area.	
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Figure	1:	Flow	diagram	of	screened,	excluded	and	included	publications	
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Table	1:	Characteristics	of	included	study	
Lee	et	al.	2009	[10]	
Methods	 Randomised,	Double-blind,	Placebo-controlled	Trial	
Participants	 173	patients	with	non-paracetamol	ALF	
Interventions	 Intravenous	NAC	or	Placebo	infused	for	72	hours.		
The	NAC	regimen	was	as	follows:	initial	loading	dose	of	150	
mg/kg/h	of	NAC	over	1	hour,	followed	by	12.5	mg/kg/h	for	4	
hours,	then	continuous	infusions	of	6.25	mg/kg/hr	NAC	for	the	
remaining	67	hours.		
Outcomes	 Primary	outcome	was	overall	survival	at	3	weeks	
Secondary	outcomes	included	transplant-free	survival,	rate	of	
transplantation,	length	of	hospital	stay	and	number	of	organ	
systems	failing	
Results		 Overall	study	
population		
Overall	survival	at	3	weeks:		
70%	(95%	CI=	60%,	81%)	NAC	group	versus	66%	(95%	CI=	56%,	
77%)	placebo	group,	p	=	0.283.	
	
Transplant-free	survival	at	3	weeks:	
40%	NAC	group	(95%	CI=	28%,	51%)	versus	27%	placebo	group	
(95%	CI=	18%,	37%),	p=0.043.	
DILI	subgroup	 Overall	survival	at	3	weeks:	
79%	(95%	CI=	58%	to	100%)	NAC	group	versus	65%	(95%	CI=	
45%	to	86%)	in	the	placebo	group,	odds	ratio	=	0.50	(95	%	CI=	
0.13,	1.98,	p=0.33).		
	
Transplant-free	survival	at	3	weeks:	
58%	(95%	CI=	33%	to	83%)	NAC	group	versus	27%	(95%	CI=	8%	
to	46%)	placebo	group,	odds	ratio	=	0.27	(95	%	CI:	0.076	to	
0.942,	p=0.04).	
Notes	 Subgroup	of	45	patients	with	non-paracetamol	DILI	provided	
data	specific	to	our	review	question.	Nineteen	patients	
received	NAC	and	26	patients	received	placebo.		
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Table	2:	Risk	of	bias	in	included	study		
Lee	et	al.	2009	[10]	
Bias	 Authors’	
judgement	
Support	for	judgement	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Method	of	randomisation	not	mentioned	
in	detail.	Randomisation	was	stratified	by	
encephalopathy	grade	with	a	blocking	
factor	of	4.	
Allocation	concealment	
(selection	bias)	
High	risk	 Not	mentioned	
Blinding	of	participants	and	
personnel	(performance	bias)	
Low	risk	 Double-blind.	Participants	and	all	study	
personnel,	except	biostatisticians	and	site	
pharmacist	were	blinded.	
Blinding	of	outcome	assessment	
(detection	bias)	
Low	risk	 Double-blind.	All	study	personnel	except	
biostatisticians	and	site	pharmacist	were	
blinded.	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Intention-to-treat	analysis.	All	participants	
analysed	in	the	group	they	were	
randomised	to.	No	missing	data.	
Selective	reporting	(reporting	
bias)	
Low	risk	 No	
Other	bias	 Low	risk	 No	
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Table	3:	GRADE	Summary	
Lee	et	al.	2009	[10] 
 
№ of patients Effect 
Quality Importance 
№ of 
studies Study design 
N-
acetylcysteine placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
 Survival in Overall Study Population 
1  
(n=173) 
randomised trials  
  
57/81 (70.4%)  61/92 (66.3%)  p = 0.283 ⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Transplant-free survival in Overall Study Population  
1 
(n=173)  
randomised trials  
  
32/81 (39.5%)  25/92 (27.2%)  p=0.043 
 
⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Adverse events (Nausea and Vomiting) in Overall Study Population 
1 
(n=173) 
randomised trials  
  
11/81 (13.6%)  4/92 (4.3%)  p= 0.031 ⨁⨁◯◯ 
LOW  
CRITICAL  
Transplantation Rates in Overall Study Population 
1 
(n=173) 
randomised trials  
  
26/81 (32.1%)  41/92 (44.6%)  p= 0.09 ⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Odds of Death in subgroup of study population with Drug-induced ALF  
1 
(n=45) 
randomised trials  
  
15/19 (78.9%)  17/26 (65.4%)  OR 0.50 
(0.13 to 1.98)  
168 fewer 
per 1,000 
(from 135 
more to 457 
fewer)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Odds of Death without transplant in subgroup of study population with Drug-induced ALF  
1  
(n=45) 
randomised trials  11/19 (57.9%)  7/26 (26.9%)  OR 0.27 
(0.07 to 0.94)  
179 fewer 
per 1,000 
(from 12 
fewer to 
242 fewer)  
⨁⨁◯◯ 
LOW  
CRITICAL  
CI: Confidence interval; OR: Odds ratio 
1. Study population includes only patients with severe liver injury i.e Acute Liver Failure (ALF). Furthermore, the aetiology of ALF is not specific to drug-
induced liver injury (DILI) only 
2. Wide 95% CI for of the point estimate 
3. Results derived from small subgroup based on aetiology 
4. Small subgroup includes only patients with severe DILI i.e. ALF 
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Table	4:	Excluded	studies	with	rationale	
Study	 Reason	for	exclusion	
Baniasadi	et	al.	2010	[34]	
	
Investigated	the	use	of	NAC	in	the	prevention	of	DILI	
Squires	et	al.	2013	[35]	
	
No	evaluable	data	in	patients	with	non-paracetamol	DILI	
Mumtaz	et	al.	2009	[11]	
	
Not	a	prospective	cohort	study	
	
Baniasadi	et	al.	2010	[35]	
Methods	 Randomised,	Open-label	Trial	
Participants	 60	patients	with	tuberculosis	commencing	antituberculous	
therapy	
Interventions	 Oral	NAC	for	initial	2	weeks	of	antituberculous	therapy	versus	
no	NAC	
Outcomes	 Primary	outcome	was	incidence	of	DILI*		
	
*DILI	defined	as:	
1. ALT	/	AST	≥	5	times	upper	limit	of	normal	
2. Raised	serum	total	bilirubin	>	1.5	mg/dl	
3. Any	increase	in	AST	and/or	ALT	above	the	pretreatment	levels	
together	with	the	hepatitis	symptoms	
Reason	for	Exclusion	 Investigated	the	use	of	NAC	in	the	prevention	of	DILI		
	
Squires	et	al.	2013	[36]	
Methods	 Randomised,	Adaptive	allocation,	Doubly	mask,	Placebo-
controlled	Trial	
Participants	 184	paediatric	patients	with	non-paracetamol	ALF	
Interventions	 Intravenous	NAC	or	Placebo	infused	for	up	to	7	days		
Outcomes	 Primary	outcome	was	one	year	survival		
Secondary	outcomes	included	liver	transplantation,	survival	
without	liver	transplantation,	length	of	hospital	stay,	
maximum	degree	of	hepatic	encephalopathy	and	number	of	
organ	systems	failing	
Reason	for	Exclusion	 No	evaluable	data	in	patients	with	non-paracetamol	DILI	
	
Mumtaz	et	al.	2009	[11]	
Methods	 Retrospective	cohort	study	
Participants	 91	Patients	with	non-paracetamol	ALF	
Interventions	 Oral	NAC	versus	no	NAC		
Outcomes	 Primary	outcome	was	overall	survival		
Secondary	outcomes	included	evaluation	of	factors	related	to	
survival	and	safety	of	NAC		
Reason	for	Exclusion	 Not	a	prospective	cohort	study	
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If	your	manuscript	refers	to	unpublished	data	(see	section	below	“References	to	data	on	file”),	you	should	
obtain	(and	provide	the	Editorial	Office	with	a	copy)	written	permission	to	mention	a	responsible	individual	
(e.g.	“Prof	X...contact	address	a.x@kcl.ac.uk)	or	should	identify	a	department	in	a	company	that	can	be	
contacted,	with	a	contact	address.	
Principal	Investigator	
For	ALL	papers	describing	investigations	of	human	subjects	(e.g.	Research	Papers)	please	indicate	which	of	
the	authors	was	the	Principal	Investigator.	(If	the	Principal	Investigator	is	not	an	author	of	the	paper,	please	
explain	why	not.)	
Reviewers	
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Authors	are	asked	to	facilitate	the	review	process	by	providing,	as	part	of	the	electronic	submission	
process	via	ScholarOne,	the	names	and	email	addresses	of	two	suitable	reviewers,	on	the	understanding	
that	the	Editors	are	not	bound	by	any	such	nomination.	
Competing	interests	
Authors	should	provide	a	statement	of	any	competing	interests	(or	affirm	that	there	are	no	competing	
interests)	within	the	submitted	manuscript.	We	will	not	reject	a	paper	simply	because	of	a	competing	
interest,	but	we	will	publish	a	statement	of	declared	interests,	or	declarations	that	there	are	no	interests,	in	
every	manuscript.	
All	authors	must	download	and	complete	a	copy	of	the	unified	disclosure	form	of	the	International	
Committee	of	Medical	Journal	Editors	(available	at	http://www.icmje.org/coi_disclosure.pdf).	They	must	
keep	a	copy	of	the	form	and	send	a	copy	to	the	corresponding	author.	Instead	of	submitting	the	form	to	the	
journal	we	require	the	corresponding	author	(or	guarantor)	to	include	a	statement	in	manuscript	body	
containing	all	interests	declared	on	all	authors’	forms	and	a	statement	affirming	that	no	declarations	were	
made	for	each	case	were	there	was	nothing	to	declare.	The	corresponding	author	must	keep	the	original	
forms	and	make	them	available	on	request.	
The	statement	should	follow	the	format	used	by	the	British	Medical	Journal	(BMJ):	
"All	authors	have	completed	the	Unified	Competing	Interest	form	at	
http://www.icmje.org/coi_disclosure.pdf	(available	on	request	from	the	corresponding	author)	and	
declare:	no	support	from	any	organisation	for	the	submitted	work	OR	[author	initials]	had	support	from	
[name	of	organisation]	for	the	submitted	work;	no	financial	relationships	with	any	organisations	that	might	
have	an	interest	in	the	submitted	work	in	the	previous	3	years	OR	[author	initials]	[had	specified	
relationship]	with	[name	of	organisation]	in	the	previous	3	years;	no	other	relationships	or	activities	that	
could	appear	to	have	influenced	the	submitted	work	OR	[initials	of	relevant	authors]	[had	specified	
relationships	or	activities	of	this	type]"	
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Copyright	–	using	the	Wiley	Author	Licensing	Service	
The	author	identified	as	the	formal	corresponding	author	for	an	accepted	paper	will,	on	acceptance	of	their	
article,	receive	an	email	prompting	them	to	login	into	Author	Services,	where,	via	the	Wiley	Author	
Licensing	Service	(WALS),	he/she	will	be	able	to	complete	the	relevant	copyright	or	licence	agreement	on	
behalf	of	all	authors	on	the	paper.	
For	authors	signing	the	copyright	transfer	agreement	
If	the	corresponding	author	does	not	select	the	OnlineOpen	option	in	WALS,	he/she	will	be	presented	with	
the	copyright	transfer	agreement	(CTA)	to	sign.	(See	here	for	further	details.)	
For	authors	choosing	OnlineOpen	
If	the	OnlineOpen	option	is	selected	the	corresponding	author	will	have	a	choice	of	the	following	Creative	
Commons	Licences	
·	Creative	Commons	Licence	Open	Access	Agreements	(OAA)	
·	Creative	Commons	Attribution	Non-Commercial	Licence	OAA	
·	Creative	Commons	Attribution	Non-Commercial	-NoDerivs	Licence	OAA	
If	a	corresponding	author	selects	the	OnlineOpen	option	and	his/her	research	is	funded	by	The	Wellcome	
Trust	and	members	of	the	Research	Councils	UK	(RCUK)	he/she	will	be	given	the	opportunity	to	publish	the	
article	under	a	CC-BY	licence	supporting	compliance	with	Wellcome	Trust	and	Research	Councils	UK	
requirements.	For	more	information	on	funder	policies,	please	see	here	and	here.	For	a	useful	guide	to	
ensuring	compliance,	see	here.	
Using	copyrighted	material	
It	is	the	author’s	sole	responsibility	to	obtain	permission	to	use	copyrighted	material,	including	print	and	
electronic	forms,	in	a	paper,	in	advance	of	submission	and	to	acknowledge	fully	the	source	of	the	material.	
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Original	Research	Articles	
Papers	should	be	concise	and	consideration	should	be	given	to	using	supporting	information	(see	
http://authorservices.wiley.com/bauthor/suppmat.asp	for	more	information	about	our	Supporting	
Information	service).	Most	original	research	articles	published	in	BJCP	are	between	3000	and	4000	words	
(for	Introduction,	Methods,	Results	and	Discussion	only).	Please	refer	to	a	recent	issue	for	examples	of	
length	that	we	regard	as	appropriate,	which	varies	with	the	complexity	and	importance	of	the	study.	If	you	
believe	your	original	research	paper	is	going	to	significantly	exceed	4000	words,	we	require	justification	for	
this	with	your	submission	letter.	
When	writing	your	paper,	original	research	papers	should	generally	be	divided	into	the	following	sections:	
Title	Page	(including	PI	Statement),	Structured	Summary,	Introduction,	Methods,	Results,	Discussion,	
Acknowledgements,	References,	tables	and	legends	to	figures	(Please	remember	that	figures	must	be	
submitted	as	separate	files).	In	addition	authors	should	provide	material	for	2	sections,	placing	this	after	
the	Structured	Summary:	
	
	
Section	1:	What	is	already	known	about	this	subject:	in	up	to	three	short	bullet	point	sentences	(not	more	
than	50	words	in	total)	summarize	the	state	of	scientific	knowledge	on	this	subject	before	you	did	your	
study	and	say	why	this	study	needed	to	be	done,	
Secion	2:	What	this	study	adds:	In	up	to	three	short	bullet	point	sentences	(not	more	than	50	words	in	
total)	give	a	simple	answer	to	the	questions	“What	do	we	now	know	as	a	result	of	this	study	that	we	did	not	
know	before?”	and	“What	take-home-message	do	you	want	to	impart	to	the	readers?”	
These	two	statements	should	be	succinct,	accurate	and	specific.	
All	Research	Papers	require	a	list	of	author	contributions.	
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Papers	should	be	concise	and	consideration	should	be	given	to	using	online	publication	of	supplemental	
tables	or	other	material	(see	http://authorservices.wiley.com/bauthor/suppmat.asp	for	more	information	
about	our	Supporting	Information	service).	
Review	articles	
Review	articles	on	a	wide	range	of	topics	appear	regularly	in	the	Journal.	Articles	may	be	unsolicited,	or	
may	be	commissioned	by	the	Reviews	Editor.	Either	kind	may	be	single	papers	or,	by	prior	agreement	with	
the	Editor,	part	of	a	themed	series.	Contributors	are	welcome	to	submit	single	review	articles	directly	
(systematic	reviews	are	especially	welcome).	Most	reviews	should	be	between	2500	and	3000	words,	
should	be	fully	referenced,	and	if	judged	potentially	suitable	will	undergo	peer	review.	Each	review	should	
include	a	summary	but	not	the	boxes	(“what	is	known”/	“what	this	adds”)	that	are	required	only	for	original	
research	articles.	They	will	be	subject	to	the	other	requirements	of	an	original	research	paper.	
From	time	to	time	the	Journal	will	publish	themed	issues,	including	review	articles	and	related	original	
research	papers.	Authors	who	want	to	suggest	a	theme	for	a	special	issue	should	contact	the	Editor-in-
Chief.	
Systematic	reviews	
The	Journal	will	publish	systematic	reviews.	The	manuscript	should	provide	a	concise	account	of	the	
methods	used,	and	concentrate	on	highlighting	key	aspects	of	interest	and	relevance	to	clinical	
pharmacologists,	under	the	following	headings:	Structured	Summary,	Introduction,	Methods,	Results,	
Discussion,	and	Conclusion.	
·	Introduction	This	should	mention	the	background	(e.g.	relevant	clinical	and	pharmacological	issues)	and	
describe	the	scope	and	aim	of	the	review.	What	was	the	reason	for	the	review?	The	strengths	and	
weaknesses	of	the	existing	literature	should	be	briefly	described,	earlier	reviews	identified	and	the	need	for	
the	present	paper	explained.	
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·	Methods	Study	selection	(search	strategy,	type	of	intervention/exposure,	types	of	studies	included,	types	
of	outcomes,	types	of	participants);	data	extraction	and	synthesis	(statistical	techniques	and	use	of	a	
quality	assessment	tool,	if	any).	
·	Results	The	key	characteristics	of	the	included	studies	and	the	main	outcome	measures;	discuss	variation	
within	and	between	studies.	
·	Discussion	Compare	the	findings	to	existing	knowledge;	outline	the	limitations	of	the	review.	
·	Conclusion	Summarize	the	key	findings	and	the	implications	for	clinical	pharmacology	and/or	practical	
drug	therapy.	
Letters	to	the	Editors	
Comments	on	previously	published	papers,	items	of	topical	interest,	and	brief	original	communications	will	
be	considered	under	this	heading.	The	length,	including	references,	should	not	exceed	800	words,	plus	one	
figure	or	table.	The	letter	should	NOT	be	divided	into	sections.	
Case	reports	(to	be	submitted	as	Letters	to	the	Editors)	
The	Journal	generally	does	not	publish	case	reports	as	full	papers	but	will	do	so	as	letters	to	the	Editor.	As	
for	other	letters	the	length,	including	references,	should	not	exceed	800	words,	plus	one	figure	or	table.	
Such	case	reports	(for	example	adverse	drug	reactions	or	interactions)	should	include	some	novel	aspect	of	
drug	action	in	man	(for	example	a	new	adverse	reaction	or	one	that	gives	insight	into	a	mechanism	or	
method	of	management).	Such	reports	may	include	single	cases	or	short	case	series.	Notes	and	guidelines	
on	the	format	for	publishing	such	reports,	including	a	structured	summary,	will	be	found	at	
http://www.bmj.com/content/suppl/2003/06/19/326.7403.1346.DC1.	
Terminology	
Stereoisomers	
When	a	drug	can	exist	as	stereoisomers	or	diastereomers	(for	example	geometrical	isomers),	the	form	of	
compound	studied	must	be	designated	as	follows	in	the	methods	section.	
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In	the	case	of	racemates	the	prefix	rac-	should	precede	the	drug	name	(for	example	rac-propranolol).	
When	possible	the	absolute	configuration	of	enantiomers	should	be	indicated	(for	example	(S)-warfarin).	
Similarly,	geometrical	isomerism	should	be	indicated	by	the	prefixes	Z/E	or	cis/trans.	When	appropriate,	
the	interpretation	of	data	obtained	using	mixtures	of	isomers	should	take	account	of	stereochemical	
aspects.	
Drug	names	
Prescribed	drugs	should	be	designated	by	an	International	Non-proprietary	Name	(recommended,	rINN,	or	
proposed,	pINN).	If	such	a	name	is	not	available,	a	drug	should	be	designated	by	its	British	Approved	Name	
(BAN;	for	example	hyoscyamine)	or	its	chemical	name	(for	example	glyceryl	trinitrate).	
When	a	mixture	of	drugs	has	a	combination	BAN	(for	example	co-trimoxazole,	co-fluampicil),	that	should	be	
used.	
For	brevity,	a	company's	code	name	may	be	used,	but	in	that	case	the	full	chemical	name	or	a	figure	
showing	the	structure	of	the	drug	should	be	given	in	the	introduction	or	a	reference	provided	that	gives	
this	information.	
Some	mediators	with	well	established	common	names	(e.g.	prostacyclin)	are	also	prescribed	as	licensed	
preparations	with	an	rINN	(e.g.	epoprostenol).	In	such	cases	the	rINN	should	be	used	in	the	context	of	
therapeutic	use.	Sometimes	English	and	American	usage	varies,	as	with	adrenaline	/	epinephrine	and	
noradrenaline	/	norepinephrine.	“Adrenaline	/	noradrenaline”	relate	clearly	to	terms	such	as	
“noradrenergic”,	“adrenergic”	and	“adrenal	gland”	but	we	will	accept	the	term	preferred	by	authors.	
Units	
SI	units	(mass	or	molar	units)	should	be	used.	If	other	units	are	used,	a	conversion	factor	should	be	included	
in	the	Methods	section.	
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Symbols	
A	set	of	standard	symbols	in	pharmacokinetics	and	pharmacodynamics	can	be	found	here.	
Structure	
Title	page	
The	title	page	should	include:	
·	the	title	giving	an	informative	and	accurate	indication	of	the	content	of	the	paper.	It	should	be	no	longer	
than	150	characters,	including	spaces;	
·	the	names,	positions,	and	addresses	of	the	authors;	
·	the	name	and	e-mail	address	of	the	submitting	author	and	the	corresponding	author,	if	different;	
·	a	running	head	of	no	more	than	75	characters,	including	spaces;	
·	keywords	(these	are	used	to	identify	potential	referees	and	as	indexing	terms);	
·	the	word	count,	excluding	the	title	page,	summary,	references,	tables,	and	figures;	
·	the	numbers	of	tables	and	figures.	
In	order	to	ensure	correct	citation	of	your	article	on	PubMed,	should	your	article	be	accepted	for	
publication,	please	include	spaces	in-between	author's	initials	on	the	title	page	of	your	manuscript,e.g.	A	E	
Smith.	If	author's	initials	do	not	appear	on	the	title	page	of	your	manuscript	according	to	these	guidelines	
they	may	appear	incorrectly	on	PubMed	until	your	article	has	been	typeset	and	published	in	an	issue.	
Summary	
The	text	must	be	preceded	by	a	structured	summary,	including	the	following	headings:	
·	Aim(s)	
·	Methods	
55	
	
·	Results	(some	numerical	data,	including	confidence	intervals	on	differences,	when	appropriate,	must	be	
included)	
·	Conclusions	
The	summary	should	be	a	maximum	of	250	words;	abstracting	services	truncate	summaries	that	are	longer.	
It	should	be	couched	in	terms	that	will	be	understood	by	most	readers	of	the	Journal.	
Analytical	methods	
Authors	should	include	details	of	the	precision,	accuracy,	sensitivity,	and	specificity	of	an	analytical	method	
used	to	measure	drugs,	metabolites	or	biomarkers	or	refer	to	other	publications	in	which	the	information	is	
given.	
·	Precision	is	a	measure	of	random	error,	usually	expressed	as	the	coefficient	of	variation.	
·	Accuracy	is	a	measure	of	systematic	error,	also	called	bias;	it	can	be	expressed	as	the	percentage	
difference	between	the	result	for	a	test	sample	and	the	reference	value	for	that	compound.	
·	Sensitivity	or	lower	limit	of	quantification.	
·	Specificity	is	the	extent	to	which	the	method	does	not	detect	compounds	other	than	those	intended.	
Statistical	methods	
In	the	Methods	section	statistical	methods	should	be	described	clearly,	with	references	when	appropriate.	
Editors	and	referees	will	be	particularly	concerned	that	any	study	described	had	sufficient	statistical	power	
for	its	purpose;	when	appropriate,	the	power	of	the	study	and	its	calculation	should	be	described	in	the	
Methods	section.	
In	the	Results	section	95%	confidence	intervals	of	differences	should	be	cited	where	relevant	for	important	
endpoints.	This	is	particularly	important	when	equivalence	is	being	claimed	(i.e.	for	non-significant	
comparisons).	The	Editors	may	utilize	specialist	statistical	referees	for	manuscript	review	where	necessary.	
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Tables	
Tables	should	generally	not	have	more	than	85	characters	to	a	line	(counting	spaces	between	columns	as	4	
characters)	and	certainly	not	more	than	110	characters	to	a	line,	unless	absolutely	unavoidable.	Each	table	
should	be	typed	on	a	separate	page	and	be	in	an	editable	format	(doc	or	xls).	
Figures	and	use	of	colour	
Please	provide	high	quality	figures	suitable	for	the	journal’s	production	processes.	Use	of	colour	(free	to	
authors)	is	encouraged	when	it	improves	the	clarity	of	the	message	conveyed.	
To	enhance	the	presentation	of	their	articles,	authors	are	encouraged	to	use	colours	in	complementary	
pairs	(example):	a	primary	pair	that	is	close	to	the	colour	of	the	journal	and	existing	tables	(example);	a	
secondary	pair	for	use	when	there	are	multiple	figures	side	by	side,	or	purely	for	variety	within	a	paper	
(example);	and	a	third	pair	to	particularly	highlight	a	figure,	possibly	in	the	conclusion/results	part	of	a	
paper	(example).	With	certain	figures	when	it	is	helpful	to	strongly	differentiate	between	sets	of	results,	the	
first	colour	of	each	pair	should	initially	be	used	(example),	with	the	corresponding	extra	colours	introduced	
as	necessary.	As	blocks,	the	suggested	colours	all	work	together	and	should	be	clear	to	those	readers	who	
are	colour-blind	(example).	Although	white	backgrounds	are	generally	advisable,	if	necessary	a	suggested	
background	colour	that	works	both	with	the	overall	look	of	the	journal,	and	the	proposed	colour	palette	is	
illustrated	(example).	
Digital	files	should	be	prepared	in	accordance	with	the	instructions	that	will	be	found	at	
http://authorservices.wiley.com/bauthor/illustration.asp.	The	eps	format	(illustrations,	graphs,	annotated	
artwork;	minimum	resolution	800	dpi)	and	tif	format	(micrographs,	photographs;	minimum	resolutions	300	
dpi)	are	recommended,	although	in	some	cases	other	formats	can	be	used.	
References	
· References	should	be	cited	using	the	Vancouver	style	(see	examples	below;	for	detailed	instructions
see	http://www.icmje.org).	
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· References	in	the	manuscript	text	should	appear	as	numbers	in	square	brackets.
· The	reference	list	should	show	the	references	in	numerical	and	not	alphabetical	order,	and	should	include
the	names	of	all	the	authors,	the	full	title	of	the	article,	the	title	of	the	publication	(abbreviated	as	in	
Medline	or	PubMed),	the	year,	the	volume	number,	and	the	first	and	last	page	numbers.	
· References	to	books	should	include	the	names	of	the	editors,	the	edition	number,	when	appropriate,	and
the	place	of	origin	and	the	name	of	the	publisher.	
· The	accuracy	of	the	references	is	the	responsibility	of	the	author.	Referencing	should	be	thorough	but	not
excessive.	Older	literature	that	has	been	well	reviewed	can	be	referred	to	indirectly	by	citing	the	review(s).	
Examples:	
1. Johnson	TN,	Rostami-Hodjegan	A,	Tucker	GT.	A	comparison	of	methods	to	predict	drug	clearance	in
neonates,	infants	and	children.	Br	J	Clin	Pharmacol	2004;	57:	677-8.	
2. Metters	J	(editor).	Independent	Steering	Committee	Report	of	an	Independent	Review	of	Access	to	the
Yellow	Card	Scheme.	London:	The	Stationery	Office,	2004.	
3. Hoffman	BB,	Lefkowitz	RJ.	Beta-adrenergic	receptor	antagonists.	In:	The	Pharmacological	Basis	of
Therapeutics,	Eighth	Edition,	eds	Gilman	AG,	Rail	TW,	Nies	AS,	New	York:	Pergamon	Press,	1990:	229-43.	
· References	to	papers	published	as	Accepted	Articles	should	be	cited	thus:	Ferro	A.	Paediatric	prescribing:
why	children	are	not	small	adults.	Br	J	Clin	Pharmacol	2015.	doi:	10.1111/bcp.12540.	
·References	to	archived	data	supporting	the	publication	should	be	cited	thus:	Brown,	LJ;	Year.Dataset	title;
Data	repository	or	archive;	Version	(if	any);	Persistent	identifier	(e.g.	DOI).	
References	to	data	on	file	
Any	assertions	within	a	submitted	manuscript	which	are	backed	up	by	reference	to	unpublished	data	
should	be	clearly	noted	as	such	in	the	body	of	the	manuscript	and	should	give	a	clear	direction	to	the	
reader	as	to	how	they	might	request	this	data:	e.g.	‘ACME34178	is	not	metabolised	by	CYP3A4	
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(unpublished	data	on	file,	ACME	Drug	Co.	Ltd.,	Didcot,	UK)’,	‘Drug	Z	is	known	to	partition	extensively	into	
erythrocytes	(personal	communication	from	Prof.	X,	University	of	Y)’	
If	making	such	a	reference	to	unpublished	data	the	author	should	obtain	(and	provide	the	Editorial	Office	
with	a	copy)	written	permission	to	mention	an	individual	(Prof	X)	or	should	identify	a	department	in	a	
company	that	can	be	contacted	with	an	address	(Department	of	Drug	Metabolism,	ACME	Drug	Co,	
drugmet@acme.com)	and	the	permission	should	come	from	the	head	of	that	department	or	their	
designate.	
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Ethical	considerations	
The	ethical	aspects	of	all	studies	involving	human	subjects	will	be	particularly	noted	when	assessing	
manuscripts.	The	methods	section	should	include	a	statement	that	the	study	was	approved	by	an	
identifiable	ethics	committee	or	similar	body	and	that	the	subjects	consented	to	the	study	after	full	
explanation	of	what	was	involved;	it	should	indicate	whether	or	not	consent	was	obtained	in	writing.	
Details	should	be	given	in	the	methods	section	of	the	approval	of	the	study	protocol	by	an	ethics	
committee	or	similar	body	and	the	approval	number	or	identification	code	should	be	provided.	The	ethics	
committee	that	approved	the	protocol	should	be	described	in	sufficient	detail	to	allow	the	committee	to	be	
identified.	
Studies	using	human	tissues	
The	Methods	section	should	contain	a	statement	that	the	study	was	approved	by	an	identifiable	ethics	
committee	or	similar	body,	and	that,	when	applicable,	explicit	patient	consent	was	obtained	for	the	use	of	
tissue	for	research.	Local	laws	(e.g.	the	Human	Tissue	Act)	should	be	adhered	to.	Where	potentially	
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relevant	(e.g.	functional	investigations)	details	of	the	donors’	drug	histories	must	be	provided.	Drug	history	
must	include	any	anaesthetic	used	for	the	biopsy.	
Supporting	Information	
Supporting	Information	can	be	a	useful	way	for	an	author	to	include	important	but	ancillary	information	
with	the	online	version	of	an	article.	Examples	of	Supporting	Information	include	additional	tables,	data	
sets,	figures,	movie	files,	audio	clips,	3D	structures,	and	other	related	nonessential	multimedia	files.	
Supporting	Information	should	be	cited	within	the	article	text,	and	a	descriptive	legend	should	be	included.	
It	is	published	as	supplied	by	the	author,	and	a	proof	is	not	made	available	prior	to	publication;	for	these	
reasons,	authors	should	provide	any	Supporting	Information	in	the	desired	final	format.	
For	further	information	on	recommended	file	types	and	requirements	for	submission,	please	
visit:http://authorservices.wiley.com/bauthor/suppinfo.asp	
Proofs	
Proofs	will	be	sent	to	the	corresponding	author	and	should	be	returned	within	3	days	of	receipt	to	the	
Production	Editor.	The	corresponding	author	will	receive	an	e-mail	alert	containing	a	link	to	a	secure	web	
site.	A	working	e-mail	address	must	therefore	be	provided	for	the	corresponding	author.	In	the	absence	of	
the	corresponding	author,	please	arrange	for	a	colleague	to	access	the	e-mail	to	retrieve	the	proofs.	
Acrobat	Reader	will	be	required	in	order	to	read	the	proof	file	and	can	be	downloaded	(free	of	charge)	from	
the	following	website:	http://www.adobe.com/products/acrobat/readstep2.html.	This	will	enable	the	file	
to	be	opened,	read	on	screen,	and	printed	out	in	order	that	corrections	can	be	made.	
Further	instructions	will	be	sent	with	the	proof.	In	your	absence,	please	arrange	for	a	colleague	to	access	
your	e-mail	to	retrieve	the	proofs.	
Corrections	should	be	kept	to	a	minimum.	Extensive	changes	may	be	charged	to	the	author.	
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Once	proofs	have	been	corrected	the	paper	will	be	published	online	in	the	next	available	issue.	The	online	
version	is	definitive	and	there	will	be	no	further	opportunity	for	correction.	The	date	of	publication	of	the	
article	is	the	date	of	its	first	appearance	online	as	an	Accepted	Article.	
Author	Services	
Author	Services	enables	authors	to	track	their	article	once	it	has	been	accepted	through	the	production	
process	to	publication	online	and	in	print.	Submitting	authors	can	check	the	status	of	their	articles	online	
and	choose	to	receive	automated	e-mails	at	key	stages	of	production,	so	that	they	don’t	need	to	contact	
the	production	editor	to	check	progress.	Visit	http://authorservices.wiley.com/bauthor	for	more	details	on	
online	production	tracking	and	for	a	wealth	of	resources,	including	FAQs,	tips	on	article	preparation,	
submission,	and	more.	
Offprints	
Free	access	to	the	final	PDF	offprint	of	your	article	will	be	available	via	author	services	only.	Please	
therefore	sign	up	for	Author	Services	if	you	would	like	to	access	your	article	PDF	offprint	and	enjoy	the	
many	other	benefits	the	service	offers.	Although	the	journal	is	now	published	online	only,	paper	offprints	
can	be	ordered	at	prices	quoted	on	the	order	form	that	accompanies	the	proofs,	provided	that	the	form	is	
returned	with	the	proofs.	
These	are	normally	dispatched	within	3	weeks	of	publication	of	the	issue	in	which	the	paper	appears;	
however	please	note	that	they	are	sent	by	surface	mail,	so	overseas	orders	may	take	up	to	6	weeks	to	
arrive.	PDF	offprints	are	sent	to	the	requesting	author	at	his/her	first	e-mail	address	on	the	title	page	of	the	
paper,	unless	advised	otherwise;	please	therefore	ensure	that	the	name,	address	and	e-mail	address	of	the	
corresponding	author	are	clearly	indicated	on	the	manuscript	title	page	if	he	or	she	is	not	the	first	author	of	
the	paper.	
The	BJCP	Prize	
The	British	Pharmacological	Society	awards	an	annual	prize	of	£1,000	for	the	best	paper	published	in	the	
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British	Journal	of	Clinical	Pharmacology	during	a	calendar	year.	Those	eligible	will	be	Registrars	in	Clinical	
Pharmacology	and	Therapeutics	(usually	ST3s	and	above)	registered	for	Higher	Medical	Training	in	the	UK	
and	the	Republic	of	Ireland	and	those	in	comparable	training	schemes	(including	PhD	schemes)	elsewhere.	
Potentially	eligible	authors	will	be	contacted	by	the	Editorial	Office	at	the	end	of	each	year	and	invited	to	
complete	an	application	form,	giving	information	about	the	provenance	of	the	work	and	the	precise	role	
played	by	the	potential	award	winner.	The	Editors	will	judge	all	entries,	but	they	may	call	for	expert	
assistance	in	making	their	decision.	Their	decision	is	final.	
Transfer	to	other	British	Pharmacological	Society	(BPS)	journals	
Pharmacology	Research	&	Perspectives	is	jointly	edited	on	behalf	of	the	BPS	and	the	American	Society	of	
Pharmacology	and	Experimental	Therapeutics	(ASPET).	
The	Editors	of	BJCP	might	consider	that	a	submitted	manuscript	is	out	of	scope	and	more	suitable	for	
consideration	by	its	sister	journals	British	Journal	of	Pharmacology	(BJP)	or	the	open	access	
journal	Pharmacology	Research	&	Perspectives.	If	so,	the	Editors	will	offer	authors	the	opportunity	to	
transfer	their	manuscript	to	the	editorial	office	of	its	sister	journals	for	consideration,	with	no	need	to	
reformat	the	manuscript.	
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